96,615 Shares in Becton, Dickinson and Company $BDX Purchased by Nuance Investments LLC

Nuance Investments LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 96,615 shares of the medical instruments supplier’s stock, valued at approximately $14,621,000. Becton, Dickinson and Company accounts for about 2.5% of Nuance Investments LLC’s holdings, making the stock its 12th biggest holding.

A number of other large investors have also recently made changes to their positions in the business. UNIVEST FINANCIAL Corp purchased a new position in shares of Becton, Dickinson and Company during the second quarter valued at approximately $251,000. K.J. Harrison & Partners Inc purchased a new stake in Becton, Dickinson and Company in the second quarter worth $1,589,000. Grandfield & Dodd LLC bought a new stake in Becton, Dickinson and Company in the second quarter valued at $293,000. BlackRock Inc. bought a new stake in Becton, Dickinson and Company in the second quarter valued at $3,721,533,000. Finally, Pallas Capital Advisors LLC purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at $920,000. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on BDX. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Bank of America reduced their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Piper Sandler raised their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. TD Cowen lifted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Finally, Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Trading Down 0.6%

Shares of NYSE BDX opened at $182.39 on Tuesday. The stock has a market cap of $50.26 billion, a P/E ratio of 54.94, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The firm has a 50-day moving average of $158.48 and a 200 day moving average of $161.26.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the firm earned $3.68 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 11,779 shares of company stock worth $1,974,669. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.